ASCO 2024 to Highlight Art and Science of Cancer Care ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.
Encouraging overall response rate of 46% and disease control rate of 98% with a median duration of response of 11.2 months seen with raludotatug deruxtecan in heavily pretreated patients Plans underway to initiate
Dr Hamilton on the Use of ADCs in Breast Cancer onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.